Sensei Biotherapeutics Inc is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases
The company leverages its proprietary platform to create personalized medicine approaches that harness the power of the immune system to target and combat tumors. By utilizing advanced science and technology, Sensei aims to transform the treatment landscape for patients through the development of novel immune-oncology solutions, with a commitment to improving clinical outcomes and enhancing patient quality of life.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
